From 2007 to 2010, 230 patients had iodine-125 seeds implanted (loose or intra-operatively linked into seed trains with variable seed-to-seed spacing). The primary aim was to evaluate differences in implant quality by comparing the intra-operative and post-implant dosimetry in patients treated with loose and intra-operatively linked seeds. The secondary aim was to evaluate the "learning curve" for the procedure. The following parameters were compared: the radiation dose to 90% of the prostate volume (D90), the radiation dose to 30% of the urethral volume (DU30), the percentage of the prostate volume receiving 100% or 200% of the prescribed dose (V100 or V200, respectively), the percentage of the rectal volume receiving 100% of the prescribed dose (VR100), and the homogeneity index (HI). We obtained the following results for loose vs. intra-operatively linked seeds: D90 (Gy), 184.7 ± 15.0 vs. 177.9 ± 12.7 (p = 0.002); V100 (%), 95.5 ± 2.4 vs. 94.9 ± 3.2 (p = 0.206); V200 (%), 35.1 ± 7.5 vs. 24.3 ± 6,9 (p < 0.001); DU30 (Gy), 218.6 ± 24.1 vs. 197.4 ± 19.5 (p = 0.001); VR100 (cm 3 ), 0.6 ± 0.47 vs. 0.3 ± 0.3 (p < 0.001); HI (%), 31.8 ± 7.3 vs. 44.0 ± 9.8 (p < 0.001). The advantages of intra-operatively linked seed implantation over loose seed implantation are a more homogeneous prostate dose and lower urethral and rectal doses. The disadvantage is a lower post-implant D90. Sufficient experience with the loose seed implantation procedure was obtained after the first 40 patients. There was essentially no learning curve when a new implantation method using intra-operatively linked seeds was subsequently initiated.
INTRODUCTION
Prostate carcinoma is one of the most common tumours in men. Early prostate cancer can be treated with radical prostatectomy, external beam radiotherapy, or brachytherapy. The seed implantation technique has several variations, including loose seeds vs. stranded seeds and pre-implant dosimetry vs. real-time dosimetry. Most published outcome data originate from centres with extensive experience in prostate brachytherapy. Despite technological progress and access to international experience, initiating a brachytherapy programme is a substantial challenge for a new centre. We started our prostate brachytherapy programme in 2007. At that time, the Mick applicator was used for loose seed implantation. In 2009, we switched to the ProLink ® delivery system (C. R. Bard, Inc., Murray Hill, NJ), which allows combining seeds and connectors into seed trains of variable length and seed-to-seed spacing. 1) Due to the rapid falloff in dose, accurate seed placement is critical for optimal dosimetry. One approach to achieving optimal dosimetry is using intra-operatively linked seeds. Intra-operatively linked seeds are not as mobile after implantation as loose seeds. Variable spacing between the intra-operatively linked seeds allows creating isodose shapes that are more adaptive to the anatomy of the prostate, urethra, and rectum. This feature makes the seed trains more similar to loose seeds than to stranded seeds, which have equal and fixed spacing between the seeds. Few studies of implant quality when using the intraoperatively linked seed implantation technique have been reported. This study compared the two implantation types and examined their learning curves. The primary aim was to evaluate the intra-operative and post-implant dosimetry differences in prostate cancer patients treated with loose vs. intra-operatively linked iodine-125 seeds. The secondary aim was to evaluate the seed implantation learning curve using dose-volume histograms.
MATERIALS AND METHODS
A total of 230 patients were treated with loose or intraoperatively linked seeds from June 2007 through December 2010. The patient and treatment characteristics are shown in Table 1 . None of the study patients used hormonal therapy.
All of the implantations were performed under transrectal ultrasound (TRUS) guidance using real-time dynamic dosimetric planning. 2, 3) The procedures were performed in an extended lithotomy position under general anaesthesia. Using a transrectal ultrasound probe attached to the stepper, transverse images from the base to the apex of the prostate were captured at 5-mm intervals and were loaded into the treatment planning software (Variseed 7.1, Varian Medical Systems, Palo Alto, CA). The prostate, urethra, and rectum were outlined. The entire prostate, from the basis to the apex but excluding seminal vesicles, was contoured. The urethra was contoured with a balloon catheter using the same slices as were used for the prostate contour. The rectal wall, including the sphincter muscle, was contoured using the same slices as were used for the prostate contour. After creating an acceptable plan, needles were placed trans-perineally in a peripherally loaded manner. Each needle location was registered in real time on the treatment planning computer by the treating physician. A secondary image capture was performed after inserting the peripheral needles, and the contours of all of the structures were revised. Next, the corrected dosimetric plan, which accounted for prostate movement and swelling after needle insertion, was generated. Once the plan was approved, loose iodine-125 seeds or intraoperatively linked seed trains were placed into the prostate. Each actual seed placement was registered using the software. The computer provided a real-time dynamic dosimetric evaluation of the implant, allowing the plan to be corrected during the procedure.
The following dosimetric targets were used for the prostate implants: prescribed dose, 160 Gy; the minimal dose received by 90% of the prostate volume (D90), > 90% of the prescribed dose; radiation dose to 30% of the urethral volume (DU30), ≤ 200 Gy; and rectal volume receiving the prescribed dose (VR100), < 1 cm 3 . All of the patients underwent computed tomography (CT) scanning for post-implant dosimetric evaluation four weeks after the seed implantation. 4) In this scan, 2.5-mm thick images were obtained at 2.5-mm intervals from 2 cm above the most superior seed to 2 cm below the most inferior seed. The images were transferred to the treatment planning sys- Abbreviations: PSA = prostate-specific antigen; TRUS = transrectal ultrasound; Low risk = PSA ≤ 10 ng/ml and Gleason sum ≤ 6; Intermediate risk = PSA 10-20 ng/ml or Gleason sum =7 All values are means +/-standard deviation.
tem for analyses by the local area network. All of the CTbased contouring and dosimetric calculations were performed by a single radiation oncologist. The entire prostate, excluding seminal vesicles, was contoured from the base to the apex. To reduce uncertainties from an indistinct prostate contour, the levator muscles were defined laterally, and the puboprostatic venous plexus was defined anteriorly. The apex was often difficult to identify, but the anterior shift of the urethra was used as a guide. The junction of the prostate and seminal vesicles was used as a guide for the superior limit of the prostate base. The urethra was contoured with a balloon catheter using the same slices as the prostate contour. The entire rectal wall was contoured using the same slices as the prostate contour.
The following dosimetric parameters were calculated for the prostate coverage evaluation: D90 (Gy), the radiation dose to 90% of the prostate volume; D50 (Gy), the radiation dose to 50% of the prostate volume; DU90 (Gy), the radiation dose to 90% of the urethral volume; DU30 (Gy), the radiation dose to 30% of the urethral volume; DU10 (Gy), the radiation dose to 10% of the urethral volume; V100 (%), the percentage of the prostate volume receiving 100% of the prescribed dose; V150 (%), the percentage of the prostate volume receiving 150% of the prescribed dose; V200 (%), the percentage of the prostate volume receiving 200% of the prescribed dose; VR100 (cm 3 ), the rectal volume receiving 100% of the prescribed dose; and HI (%), the homogeneity index. The homogeneity was defined as 5) .
The HI measures the fraction of the prostate volume receiving between 100% and 150% of the prescribed dose. For a homogeneous implant, the HI approaches 100%.
All of the parameters were calculated for both the intraoperative (US-based) and post-implant (CT-based) datasets. The data were stored in a custom-programmed database. The statistical data analyses were conducted using the STATIS-TICA 8.0 statistical package. The quantitative variables are described as arithmetic means and standard deviations. Comparisons between two independent groups were evaluated using the Mann-Whitney and Wilcoxon tests. The study was approved by the Regional Ethics Committee of Biomedical Research (No. BE-2-9).
RESULTS
The intra-operative and post-implant dose-volume parameters (means ± standard deviation) differed significantly ( Table 2 ). The mean intra-operative prostate D90 was 185.8 ± 8.2 Gy, and the post-implant value was 175.3 ± 21 Gy (p < 0.001). The mean intra-operative DU30 was 194.6 ± 7.4 Gy, and the post-implant value was 207.8 ± 27.0 Gy (p < 0.001). The intra-operative VR100 was 0.19 ± 0.16 cm 3 , and the post-implant value was 0.55 ± 0.65 cm 3 (p < 0.001). Figure  1 presents the frequency distributions of the intra-operative and post-implant D90 values. The post-implant D90 measure had a lower mean value and broader distribution (175.3 ± 21.9 Gy) than did the intra-operative D90 measure (185.8 ± 8.2 Gy) (p < 0.001). Although the post-implant dosimetric values differed significantly from those achieved during the implantation procedure, 91.3% of the implants met the D90 prostate quality requirements.
To analyse the time trends of and learning curve for the iodine-125 seed implantations, the patients from each group (loose seeds and linked seeds) were divided into subgroups of 20 according to the time when their implantations were performed. For the initial cohort of 40 patients who were implanted with loose seeds, the mean post-implant D90 was 151.9 ± 31.2 Gy. A significant difference in the post-implant D90 was detected for the patients who received their implants after 40 procedures had been performed (180.2 ± 13.8 Gy vs. 151.9 ± 31.2 Gy, p < 0.001). The changes in the post-implant D90 values for the different subgroups are presented in Fig. 2 .
Similar trends were observed for the V100, DU30, VR100, and HI. The mean V100 for the first 40 patients treated with loose seeds was 87.2 ± 10.1%; for the patients treated with loose seeds after the first 40, the mean V100 was 95.1 ± 3.0% (p < 0.001). The mean DU30 for the first 40 patients treated with loose seeds was 220.5 ± 37.1 Gy; for the patients treated with loose seeds after the first 40, it was 204.9 ± 23.5 Gy (p < 0.001). The mean VR100 for the first 40 patients treated with loose seeds was 1.2 ± 1.0 cm 3 ; for the patients treated with loose seeds after the first 40, it was 0.4 ± 0.4 cm 3 (p < 0.001). The mean homogeneity index for the first 40 patients treated with loose seeds was 35.1 ± HI V V V = − × 100 150 100 100% 11.5%; for the patients treated with loose seeds after the first 40, it was 39.8 ± 10.7% (p < 0.016). After loose seed implantation was performed on 106 patients, the implantation method was changed from loose seeds to intra-operatively linked seeds. For the implants with intra-operatively linked seeds, there were no significant differences in the D90, V100, D U 90, V R 100 or HI values between the first and the subsequent patient groups.
The patients were treated with loose seeds between 2007 and 2009, and in 2009, we started using intra-operatively linked seeds. Our analysis shows that the learning period covered the first 40 patients treated with loose seeds. We were already experienced with the implantation procedure when we switched to intra-operatively linked seeds, and there was no learning curve for the patients treated with intra-operatively linked seeds. When comparing the dosimetry parameters between the two implant techniques, we excluded the first 40 patients of the loose seed group. The patient data and characteristics without the learning curve are presented in Table 1 . The baseline clinical values and intra-operative and four-week post-implant evaluations were comparable for the patients receiving the different implant types.
There was no difference in operative time between the two implant methods. The mean operative time for the loose seed implantation was 2.6 hours compared to 2.5 hours for intraoperatively linked implantation (p = 0.649). Five patients (4.7%) in the loose seed group reported seed prolapse during urination. No seed losses were recorded in the intra-operatively linked seed group. No special exams were performed to check for seed migration to the lungs. There was no significant difference in the main intra-operative dosimetric parameter, D90, between the loose and linked seed groups, but the prostate D50, V100, V150, and V200, the urethra D90, and the rectum V100 were significantly higher in the loose seed group. The implant homogeneity index was also significantly higher in the intra-operatively linked seed group (p < 0.001). In addition, the post-implant results were more favourable for the intra-operatively linked seed implants, with statistically significant differences being observed in the V100, V150, V200, D U 30, D U 10, V R 100, and HI values (Table 3, Fig. 3 ). The mean post-implant D90 was the only measure that was more favourable for the intraoperatively linked seed group (177.9 ± 12.7) than for the loose seed group (184.7 ± 15.0) (p = 0.002).
DISCUSSION
The prostate cancer patients treated at our institution with iodine-125 seed brachytherapy during 2007-2010 received an average dose (D90) of 175.3 ± 21 Gy, which could be considered an adequate dose for treating early prostate cancer. However, the CT-based post-implant dosimetry revealed patients with D90 values < 100 Gy and others with values > 220 Gy. Lower doses may lead to treatment failure, and higher doses may damage the rectum and urethra. The issues of implant quality and total dose vs. outcome have been extensively investigated over the past ten years. Several studies have shown improved results with higher doses or improved implant quality, [6] [7] [8] [9] [10] [11] [12] while others have not. 13) In the majority of studies, implant quality was evaluated by measuring the prostate D90, V100, and HI. The clinical importance of other dosimetric parameters, such as the prostate V150, V200, and D50, is unclear. The post-implant prostate D90 and V100 values should be close to the intra-operative values, the dose should be as homogeneous as possible, and the doses to the rectum and the urethra should not exceed safe levels (a lower dose or a smaller irradiated volume is preferred). The present study found better results from intraoperatively linked seeds than from loose seeds. To clarify the differences between the two methods and their advantages and disadvantages, the significant results are shown in Table  4 . There were no significant differences between the loose and intra-operatively linked seed groups in the intra-operative or post-operative prostate V100. The intra-operative prostate D90 did not differ significantly between the two types of implants. A slightly higher post-implant D90 was seen in the loose seed group than in the intra-operatively linked seed group (184.7 ± 15.0 Gy vs. 177.9 ± 12.7 Gy, p = 44.0 ± 9.8 < 0.001* Abbreviations: D90 (Gy) = the radiation dose to 90% of the prostate volume; D50 (Gy) = the radiation dose to 50% of the prostate volume; DU90 (Gy) = the radiation dose to 90% of the urethral volume; DU30 (Gy) = the radiation dose to 30% of the urethral volume; DU10 (Gy) = the radiation dose to 10% of the urethral volume; V100 (%) = the percentage of the prostate volume receiving 100% of the prescribed dose; V150 (%) = the percentage of the prostate volume receiving 150% of the prescribed dose; V200 (%) = the percentage of the prostate volume receiving 200% of the prescribed dose; VR100 (cm 3 ) = the rectal volume receiving 100% of the prescribed dose; HI (%) = the homogeneity index (the fraction of the prostate volume receiving between 100% and 150% of the prescribed dose). *statistically significant. 0.002). One possible explanation for the deterioration in the post-operative dose after a stranded seed implantation may be retraction of the strands during or after the implantation procedure. Moerland et al. have hypothesised that stranded seeds placed partially inferior to the apex of the prostate may anchor in the surrounding tissue and, therefore, may be redrawn from the prostate by subsequent muscle contractions when released from the locking needles. 14) Mclaughlin et al. observed a differential z-axis shift of strands versus the prostate, as visualized on MRI, with the prostate shifting superiorly relative to the seeds. 15) These researchers hypothesised that this effect was caused by compression of the levator ani muscle, thereby leading to anchoring of the stranded seeds and, finally, to retraction. A second explanation may be that because loose seeds are not interconnected, they can track when the prostate expands due to oedema, whereas stranded seeds cannot, due to their interlinked connection. Most studies support the predictive value of the D90. 12, 6) Lower doses (e.g., D90 ≤ 130 Gy vs. > 130 Gy) have been used in the majority of the studies that showed correlations between D90 and treatment results (lower biochemical relapse rates and fewer positive biopsies). In one study, prostate implants with a D90 < 90% of the prescribed dose had an 80.4% 4-year PSA relapse-free survival (RFS), while those with a D90 ≥ 90% of the prescribed dose had a 92.4% 4-year PSA RFS (p = 0.001).
12) Stock et al. have reported a significant (92%) 4-year freedom from biochemical failure for implants with D90 > 140 Gy and a 68% 4-year freedom for those with D90 ≤ 140 Gy (p = 0.02).
6) The D90 results in our study differed significantly (184.7 ± 15.0 Gy for loose seeds vs. 177.9 ± 12.7 for intra-operatively linked seeds), but this difference may have little clinical impact. The lower prostate V150 and V200, higher homogeneity index, and lower D U 10, D U 30, and V R 100 (both intra-operatively and post-implant) showed that intra-operatively linked seeds achieve a homogeneous dose distribution inside the prostate. Greater homogeneity can be achieved by increasing the number of implanted seeds. Despite the larger number of implanted seed in the loose seed group, greater dose homogeneity was observed in the intra-operatively linked seed group of our study. Intraoperatively linked seeds allow avoiding redundant irradiation of the selected prostate regions and minimising the urethra and rectum doses.
The major weakness of the loose-seed technique is the possibility of seed migration, and the fixed spacing between seeds is a common limitation for stranded seeds. The ProLink ® delivery system allows combining the seeds and connectors of intra-operatively linked seeds into seed trains of variable length and seed-to-seed spacing, depending on the treatment plan. The previous data comparing the prostate dosimetry of loose and stranded seeds are presented in Table 5 .
Some studies comparing loose seeds with stranded seeds have reported higher prostate V100 and D90 values for stranded seeds in the post-implant dosimetry. 16, 17) The explanation for the superior post-implant prostate D90 and V100 results with stranded seeds is the decreased seed migration. Other researchers have not observed any dosimetric advantages to stranded seeds. 18, 21) Saibishkumar et al. found that the intra-operative prostrate dosimetric parameters were greater for loose seeds than for stranded seeds; by days 7 and 30, however, the dosimetry of the two approaches was similar. 21) Improved intra-operative dosimetry may be explained by better prostrate dose distribution, due to the varying spacing between loose seeds. Due to the considerable postimplantation seed migration with loose seeds, the prostate D90 and V100 values decrease. In our study, by contrast, most of the intra-operative dosimetric parameters remained stable when the post-implant dosimetry was performed Higher HI (%) Higher HI (%)
Abbreviations: D90 (Gy) = the radiation dose to 90% of the prostate volume; D50 (Gy) = the radiation dose to 50% of the prostate volume; DU90 (Gy) = the radiation dose to 90% of the urethral volume; DU30 (Gy) = the radiation dose to 30% of the urethral volume; DU10 (Gy) = the radiation dose to 10% of the urethral volume; V100 (%) = the percentage of the prostate volume receiving 100% of the prescribed dose; V150 (%) = the percentage of the prostate volume receiving 150% of the prescribed dose; V200 (%) = the percentage of the prostate volume receiving 200% of the prescribed dose; VR100 (cm 3 ) = the rectal volume receiving 100% of the prescribed dose; HI (%) = the homogeneity index (the fraction of the prostate volume receiving between 100% and 150% of the prescribed dose).
(after 1 month). The main reason for the improved intraoperative and post-implant dosimetry results when using intra-operatively linked-seed implantation, rather than looseseed implantation, may be the decreased seed migration inside and outside of the prostate. Only one study has compared the dosimetry results of intra-operatively linked seeds to those of loose seeds. In contrast to our study, no statistically significant difference in the D90 was found between the two methods.
23) The data in our study indicated better results from linked seeds. The prostate V100, V150, V200, and HI, the urethral D U 10 and D U 30, and the rectal V R 100 for intra-operatively linked seeds were superior to those of loose seeds. It should be noted that we did not use classical equally stranded seeds but, rather, linked seed trains with variable length and seed-to-seed spacing. Intra-operatively linked seeds probably combine the advantages of both types of implants (the improved prostrate geometry of loose seeds and the decreased migration of stranded seeds), leading to simple implantation procedures with favourable postimplant dosimetric parameters.
Quality control is especially important for centres that are implementing seed implantation in clinical practice or are switching between various implantation techniques. Remarkable trends have been reported for brachytherapy experiences. Bladou et al. reported a learning curve over the first 20-30 cases that resulted from improved coverage of the basal and anterior portions of the prostate after analysing the initial dosimetric assessments. 24) Hoinkis et al. found that 18 cases were required before their D90 learning curve plateaued. 25) Lee et al. also found significant dosimetric differences between their first 30 cases and their subsequent procedures. 26) Liu et al. reported that the number of patients with D90 < 140 Gy decreased steadily as their implant programme matured (odds ratio = 0.56 per year, p < 0.001). 27) Large analysis (about 1,473 patients) by Butler et al. showed an even longer learning curve that extended over hundreds of patients. 28) However, the majority of data on learning the procedure refer to the pre-planned implantation method. Centres in which brachytherapy programmes using real-time techniques were started de novo have reported successful initiations of their implantation programmes with no learning period at all. 29) Our findings also support the hypothesis that a brachytherapy programme can be successfully launched in the proper environment (modern hardware and software, adequate training and initial supervision). Beginning with the initial implantations, we were able to achieve the predefined dosimetric goals in most of our patients. However, our time-based implantation analysis showed significant dosimetry differences between the early and later procedures. It took us about 40 implantation procedures before the implant parameters stabilised. The learning curve was observed in the prostate D90, prostate V100, urethral DU30, rectal VR100, and homogeneity index. If the quality of the implant is poor (if the seeds are inaccurately placed, for example), all of the dosimetry parameters suffer. Lower prostate D90 and V100 values are associated with higher rectal VR100 and urethral DU30 values and with a lower homogeneity index. There are no data in the literature about the learning curve when a new implantation modality is initiated in centres that are experienced with another implant method. This study found essentially no learning curve when we implemented the intra-operatively linked seeds method after we had significant experience with the loose-seeds approach.
CONCLUSIONS
Intra-operatively linked seed implantation has the following advantages over loose-seed implantation: a more homogeneous dose to the prostate and a lower dose to the urethra and the rectal wall. The disadvantages of intra-operatively Abbreviations: D90 (Gy) = the radiation dose to 90% of the prostate volume.
linked seeds are a lower post-implant D90 and higher intraoperative D U 90. The analysis of the post-implantation dosimetric data demonstrated that sufficient experience with the loose-seed approach was obtained after the first 40 patients. There was essentially no learning curve when we implemented the intra-operatively linked seeds method after we had significant experience with the loose-seeds approach.
